This morning regenerative medicine business Mesoblast Limited (ASX: MSB) reported a net loss before income tax benefits of US$90.2 million (A$113 million) for the financial year ending June 30, 2017. The biotech posted revenues for the year of US$2.4 million and after recently raising US$40 million now has cash on hand of US$84 million.
While the huge losses look bad the company is still valued at more than $600 million thanks to what some consider to be its large potential to generate commercial sales for its regenerative medicine stem cell therapy treatments for the likes of back pain, rheumatoid arthritis, or chronic heart failure.
The company has multiple clinical trials at various stages of progress all of which are aimed at proving the efficacy of its stem cell therapies in treating these common human ailments with new medical technologies.
However, these trials are costly with the company boasting much more promise than delivery over its life as a publicly traded business so far. Given its large losses investors might want to watch this business from the afar. Today shares change hands for $1.42 and are down 77% over the past five years.
If you're looking for solid income from dividend stocks, look no further. The Motley Fool's top dividend analyst, who leads our dividend stock newsletter, Dividend Investor, recently picked what he believes are the best dividend stocks in the market right now.
These dividend cash cows -- paying franked and fully franked dividends -- could be the latest in a list of top stocks Dividend Investor has picked over the years.
Click here to learn how you can get access!
Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.